KANSAS CITY, Mo. — A researcher says he may have discovered a potential alternative treatment for severe blood loss that could someday supplement traditional blood transfusions.

Dr. Cutberth Simpkins, founder of Vivacelle Bio, said experimental testing of the treatment has produced promising results in animals experiencing hemorrhagic shock.

According to Simpkins, survival rates in testing have approached 100% when the treatment was administered through arteries during severe blood-loss events.

The treatment remains experimental and would require additional testing and regulatory approval before becoming available for use in people. Researchers say future patients could potentially receive up to two liters of the treatment if it ultimately gains approval.